No Data
The enthusiasm for pharmaceutical companies going public in Hong Kong continues! Two leading COVID-19 drug companies are entering the market. How can they break the dilemma of single revenue sources?
In the past three months, nearly 20 pharmaceutical companies have submitted listing applications to the Hong Kong Stock Exchange, including True Biologics and Wangshan Wangshui, two former stars in the COVID-19 pharmaceutical industry; the primary revenue of these two companies is still concentrated on products related to COVID-19 authorization or commercialization, which has significantly declined, providing limited Cash / Money Market.
BOCOM INTL: There is significant room for recovery in the mainland pharmaceutical Sector, and the foreign investment environment is expected to improve.
Subsequent bullish policies for finance and medical insurance/commercial insurance are expected to continue to be introduced, and the overall valuation of the sector remains at a historical low, indicating significant room for recovery in the sector, thus giving the mainland pharmaceutical Industry a "leading" rating.
China Merchants Bank International: The pricing policy for pharmaceuticals in the mainland is expected to be optimized, and FSG Medical Serv A accelerates commercialization.
Benefiting from the optimization of domestic Pharmaceutical price policies, improvements in the domestic macro environment, and expectations of interest rate cuts overseas, the Industry is expected to continue experiencing valuation recovery in 2025.
Is Trump’s risk disturbing the market? Pharmaceutical stocks have suddenly changed, and the WuXi group has collapsed entirely!
Under the AI boom, the Biomedical and AI Medical stocks have been running wild this year.
Innovent Biologics Anti-Cancer Drug's NDA Accepted by China's NMPA; Shares Slide 3%
[Brokerage Focus] China Securities Co.,Ltd.: With policies and technology driving together, the competitiveness of China’s Innovative Drugs Industry continues to rise.
Jingwu Financial News | China Securities Co.,Ltd. research points out that from a policy perspective, centralized procurement and medical insurance negotiations have entered a normalized stage, and commercial Insurance has brought potential growth space to the Innovative Drugs market, with expectations for further support for Innovative Drugs in the future. In the technology sector, in 2023, the Global sales of ADC drugs reached 10.4 billion USD, and domestic enterprises have accelerated their layout and research and development in the ADC field, gradually entering a period of fruitful results. The GLP-1 weight loss sector has now matured, and market competition has upgraded from merely weight loss efficacy to multiple health benefits, with new target drugs in.
